The Thai phase III clinical trial (RV144) using the recombinant poxvirus vector ALVAC and the protein gp120 in a prime-boost strategy and showing a 31.2% protection against HIV infection [1], has raised considerable interest in the use of improved attenuated poxvirus recombinants as HIV vaccine candidates. Here, ITIH4 is linked to HIV infectious disease.